Fruquintinib combined with cadonilimab and nab-paclitaxel as second‑line treatment for advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC) (ESMO Asia 2026) - Oct 1, 2026 - Abstract #1096P; Pres time: Dec 4, 2026; 05:15 PM - 06:15 PM; Location: Poster area (Exhibition); No abstract available
Clinical • Metastases • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Junction Adenocarcinoma • Oncology • Solid Tumor
|
|
Weijian Guo; Jieyun Zhang; Chenchen Wang; Qirong Geng; Mingzhu Huang; Wanjing Feng; Jianhua Chen; Xiaodong Zhu
|